CPRX - Catalyst Pharmaceuticals, Inc.
2.88 +0.11 (3.97%)
After hours: 4:51PM EST
| Previous Close | 2.88 |
| Open | 2.86 |
| Bid | 2.77 x 1100 |
| Ask | 2.84 x 1000 |
| Day's Range | 2.68 - 2.91 |
| 52 Week Range | 2.18 - 4.51 |
| Volume | 2,985,025 |
| Avg. Volume | 909,990 |
| Market Cap | 284.587M |
| Beta (3Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of CPRX earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Catalyst Pharmaceuticals Inc Earnings Call
- Associated Press•5 days ago
Catalyst: 3Q Earnings Snapshot
The Coral Gables, Florida-based company said it had a loss of 8 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•5 days ago
Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., Nov. 07, 2018 -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical.
- GlobeNewswire•12 days ago
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release third quarter 2018 financial results after market close on Wednesday, November 7, 2018. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Thursday, November 8, 2018 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
- GlobeNewswire•last month
Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX) Shift From Loss To Profit
Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX): Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. The US$318.1m market-cap postedRead More...
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York City Cantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla., ...
- Zacks•2 months ago
Catalyst (CPRX) Up 16% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SmarterAnalyst•2 months agoHealthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 20th Annual Global Investment Conference, which is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3.
SmarterAnalyst•3 months agoWhy Catalyst Pharmaceuticals (CPRX) Is a $6 Stock
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company's flagship candidate Firdapse approved, but they may not have to wait much longer -- the FDA is expected to make a decision by November 28. Catalyst had previously submitted an NDA for Firdapse off one positive pivotal trial in Lambert-Eaton myasthenic syndrome (LEMS). While the company believed this single trial, together with other information, would be adequate for approval, the FDA issued a Refuse-to-File letter in early 2016.
- ACCESSWIRE•3 months ago
Catalyst Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM ...
- Associated Press•3 months ago
Catalyst: 2Q Earnings Snapshot
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks
WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).
- ACCESSWIRE•5 months ago
Free Research Reports on Catalent and Three More Generic Drugs Stocks
Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.
- ACCESSWIRE•6 months ago
Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGRX as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted final approval to the Company's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Active-Investors.com is currently working on the research report for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), which also belongs to the Healthcare sector as the Company Eagle Pharma.
- Associated Press•6 months ago
Catalyst: 1Q Earnings Snapshot
The Coral Gables, Florida-based company said it had a loss of 6 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
